

23<sup>rd</sup> Oct 2019

Gilead Sciences, Inc.  
333 Lakeside Drive Foster City,  
CA 94404  
Attention: General Counsel  
Facsimile: (650) 522-5537

Medicines Patent Pool  
150 route de Ferney,  
P.O.Box 2100 CH-1211  
Geneva 2, Switzerland  
Attention: General Counsel  
Email: Office@medicinespatentpool.org

Subject: Termination Notice for COBI (Cobicistat) & EVG (Elvitegravir)

Reference: Licence Agreement dated 7th April 2016, as amended on 7 December 2017 executed by and between Gilead Sciences, Inc., Medicines Patent Pool (MPP) and Aurobindo Pharma Ltd.

Dear Sir/Madam,

This is to provide notice pursuant to Section 10.5 of the above-referenced License Agreement of Aurobindo's intention to terminate its license for COBI (Cobicistat) & EVG (Elvitegravir), effective immediately.

We look forward to a continued fruitful and collaborative relationship with Gilead Sciences and the MPP"

Yours Sincerely,



**Umesh Krishnamoorthy,**  
Vice President,  
Global Antivirals,  
Aurobindo Pharma Ltd



**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)